Given its higher valuation, we consider that Pfizer inventory (NYSE: PFE) is at present a greater choose than its business peer – AbbVie stock (NYSE:ABBV). PFE inventory trades at a a lot decrease a number of of 11x ahead, versus 20x for ABBV, and we predict this hole in valuation will slender in favor of Pfizer within the coming years. Though Pfizer has seen higher income development in recent times, AbbVie is extra worthwhile. There may be extra to the comparability, and within the sections under, we focus on why we predict Pfizer will outperform AbbVie within the subsequent three years. We examine a slew of things, corresponding to historic income development, returns, and valuation.
1. AbbVie Inventory Has Fared A lot Higher Than Pfizer
PFE inventory has seen little change within the final three years, whereas ABBV inventory has seen robust positive aspects of 115% from ranges of $90 in January 2021 to round $195. This compares with a rise of about 45% for the S&P 500 over this roughly three-year interval. Nevertheless, the adjustments in these shares haven’t been constant. Returns for PFE had been 67% in 2021, -10% in 2022, and -41% in 2023, whereas that for AbbVie had been 32%, 24%, and 0%, respectively. Compared, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that each PFE and ABBV underperformed the S&P in 2023.
Actually, persistently beating the S&P 500 — in good occasions and dangerous — has been troublesome over current years for particular person shares; for heavyweights within the Well being Care sector together with UNH and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. In distinction, the Trefis High Quality (HQ) Portfolio, with a set of 30 shares, has outperformed the S&P 500 every year over the identical interval. Why is that? As a gaggle, HQ Portfolio shares supplied higher returns with much less threat versus the benchmark index; much less of a roller-coaster journey, as evident in HQ Portfolio performance metrics.
2. Pfizer Has Seen Higher Income Development
Pfizer’s income rose at a mean annual charge of 25.6% from $41.7 billion in 2020 to $58.5 billion in 2023, whereas AbbVie’s income grew at a mean charge of 6.5% from $45.8 billion to $54.3 billion over this era.
Pfizer’s income over 2021 and 2022 surged resulting from a really excessive demand for its Covid-19 vaccine and remedy. However this pattern reversed in 2023, with its whole gross sales falling a big 42% y-o-y, amid decrease Covid-19 vaccine demand. Currently, the corporate is dealing with elevated competitors for its blockbuster vaccine – Prevnar – which noticed its gross sales development gradual to 1.6% final 12 months versus 20.2% development in 2022. On the constructive facet, a powerful uptick in Vyndaqel and Abrysvo has aided the general gross sales development currently. Pfizer can also be benefiting from its Seagen acquisition, which is anticipated so as to add $10 billion to the corporate’s top-line by 2030, in comparison with the $3 billion contribution anticipated in 2024.
AbbVie’s income development has been buoyed by its Allergan acquisition in 2020. The corporate is finest recognized for its blockbuster drug – Humira – used to deal with rheumatoid arthritis and Crohn’s illness, amongst others. Humira’s gross sales peaked at $21.2 billion in 2022, earlier than falling 32.2% y-o-y to $14.4 billion in 2023. This may be attributed to the biosimilar competitors.
AbbVie, to some extent, can fight the lack of income from Humira by market share positive aspects for a few of its comparatively new medication, primarily Skyrizi, and Rinvoq. These medication are used to deal with plaque psoriasis and rheumatoid arthritis. For perspective, these two merchandise garnered $11.7 billion in 2023, reflecting a stable 53% y-o-y development. The gross sales of its anti-depressant – Vraylar – additionally spiked 35% y-o-y to $2.8 billion in 2023. For the six-month interval ending June 2024, Skyrizi and Rinvoq continued their market share positive aspects, with gross sales rising 50% y-o-y to over $7 billion.
AbbVie can also be inorganic development. After its acquisition of Allergan in 2020, it acquired ImmunoGen for $10.1 billion this 12 months, giving it rights to Elahere — an ovarian most cancers remedy – with estimated peak gross sales of over $2 billion.
Wanting ahead, we count on each Pfizer and AbbVie’s gross sales to rise at a mid-single-digit common charge for the subsequent three years.
3. AbbVie Is Extra Worthwhile
Pfizer’s reported working margin declined from 21.2% in 2020 to 5.7% in 2023, whereas that for AbbVie contracted from 27.8% to 24.9% over this era. Pfizer incurred restructuring prices and acquisition associated costs related to Seagen that has weighed on its margin. Pfizer is engaged on a cost-cutting initiative, focusing on $4 billion in financial savings by the top of this 12 months. This can assist the corporate develop its margin profile.
4. AbbVie Fares Higher In Phrases of Monetary Threat
Taking a look at monetary threat, we consider AbbVie has an edge over Pfizer. Its 20% debt as a proportion of fairness is decrease than 41% for Pfizer. Additionally, its 9% money as a proportion of property is larger than 3% for Pfizer. This means that AbbVie has a greater debt place and extra cash cushion.
5. The Internet of It All
We see that AbbVie is extra worthwhile and provides decrease monetary threat than Pfizer. Now, prospects, we consider Pfizer is the higher selection of the 2, given its higher prospects and valuation. Pfizer’s second-quarter outcomes for this 12 months had been constructive for the corporate, reflecting a 3% y-o-y rise in gross sales, regardless of decrease contribution from Covid-19 merchandise. Excluding these merchandise, gross sales had been up 14%. Moreover, Pfizer’s cost-cutting initiative will bolster its earnings development. At its present ranges, PFE inventory is buying and selling at 11x ahead anticipated earnings of $2.62 on a per share and adjusted foundation in 2024. The 11x determine is far decrease than the inventory’s common P/E ratio of 15x seen over the past 5 years.
Compared, at its present ranges of round $195, AbbVie inventory trades at 18x anticipated 2024 earnings of $10.88 per share. This compares with the 12x common P/E a number of for ABBV seen over the past 5 years. This means that PFE inventory has some room to develop, whereas ABBV inventory seems totally priced, in our view.
| Returns | Sep 2024 MTD [1] |
2024 YTD [1] |
2017-24 Complete [2] |
| PFE Return | 2% | 8% | 24% |
| ABBV Return | -1% | 29% | 334% |
| S&P 500 Return | -3% | 15% | 146% |
| Trefis Strengthened Worth Portfolio | -5% | 8% | 704% |
[1] Returns as of 9/12/2024
[2] Cumulative whole returns for the reason that finish of 2016
Make investments with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
